TAK

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$15.96 -1.18%

Recent alerts on TAK

All signals →

SEC filing TAK Plans to Revise FY2025 Financial Results Due to $X Loss from AMITIZA Antitrust Litigation Verdict

SEC filing TAK Outlines Executive Compensation Strategy, Ties Pay to Performance with 30% Relative TSR Modifier, Emphasizes Long-term Shareholder Value Creation

SEC filing TAK Reports FY2025 Pipeline Progress, Positive Phase 3 Results for Oveporexton, Zasocitinib, Advances Rusfertide, TAK-881 Trials

Short volume Short volume 71% of volume (3.9σ)

News Jury Hits Takeda With $885 Million Antitrust Verdict

SEC filing TAK Reports May 2026 Monthly Results, No Specific Financial Data Provided

News Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

News Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

News Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs

News UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients

News Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed

News Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

News Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

News Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

News Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production

News FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

News OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

News Takeda found guilty in 'pay-for-delay' scheme over Amitiza

SEC filing TAK Extends Stock Compensation Plan for Directors & Japan Management, BIP Trust

News Takeda Pharmaceutical Non-GAAP EPS of ¥517.00, revenue of ¥4505.7B; gives FY2026 forecast

News Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

News Takeda revamps business seeking ¥200B in savings by FY28

News FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer

News Takeda, Iambic ink AI drug discovery deal worth more than $1.7B

News Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio

Get push alerts for TAK

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS